Navigation Links
Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
Date:6/2/2011

ared to the placebo patients of the same age.

These observations were supported by an age-related subgroup analysis that showed dosing-compliant patients age 70 and over (approximately the oldest three quartiles of the patients evaluable at the end of the study) demonstrated statistically significant improvements in two of the three cognitive scoring measurements in the reaZin treatment group compared to the placebo group. As presented below, in this subgroup, two of the three standard cognitive measures reached statistical significance (p < 0.05) as determined by the p-values (the average changes in cognitive scores from baseline to 6 months in the treatment group compared to the placebo group). The p-values were as follows:

  • ADAS-Cog - Alzheimer's Disease Assessment Scale - Cognitive Subscale p-value: 0.037
  • CDR-SOB - Clinical Dementia Rating Scale - Sum of Boxes p-value: 0.032
  • MMSE - Mini Mental State Examination p-value: 0.067

Based upon the apparent cognitive benefit observed in these older patients who were managed with reaZin in comparison to patients who received the matching placebo, Adeona is preparing a larger clinical study protocol to evaluate patients diagnosed with mild to moderate Alzheimer's disease who are age 70 and over. It is anticipated that the clinical study will enroll over 100 patients and that the evaluation period will be at least 12 months. The intention is to develop the Company's proprietary zinc-based tablet as a drug (in parallel with making reaZin available as a prescription medical food) and to conduct this new clinical study under an Investigational New Drug (IND) application to be filed with the Food & Drug Administration (FDA).

"The biological availability of zinc is impaired in Alzheimer's disease as evidenced by significantly lower plasma zinc levels and deficiencies of neuronal zinc activities, each of which
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller
2. Adeonas Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant
3. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Anesiva Announces Second Quarter 2008 Financial Results and Update
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
9. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. ThirdBiotech Announces Kemeta as Newest Sponsor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... (PCR) TECHNOLOGY: GLOBAL MARKETS , the global market for ... billion in 2013. This is estimated to grow to ... growth rate (CAGR) of 28.6%. , New digital PCR ... possibilities within the broader PCR field. The opportunities presented ...
(Date:7/11/2014)... EPFL and the University of  Geneva  (UNIGE) ... P. Donoghue . The American neuroscientist is to head ... The new Wyss Center for Bio- and Neuro-Engineering, ... , has named as its director one of the ... founder of Brown University,s Institute for Brain Science, has ...
(Date:7/11/2014)... ON , July 11, 2014 /CNW/ - Sunovion ... approved APTIOM TM (eslicarbazepine acetate) for use as ... seizures in patients with epilepsy who are not satisfactorily ... indicated for use in patients under 18 years of ... most common neurological disorders and according to Epilepsy Canada, ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... Cell Therapeutics (CTI),(Nasdaq and MTA: CTIC) announced today that ... on February 27, 2009 in lieu of the Special,Meeting ... February 6, 2009.,Shareholders of record at the close of ... the Board of Directors, will be entitled to vote ...
... NVAX ) a clinical-stage vaccine company, announced ... Officer, will be presenting at the Phacilitate Vaccine Forum ... Grand Hyatt in Washington D.C. Dr. Heaton is ... technologies and other novel vaccine manufacturing solutions providing in ...
... Geron to Study GRNOPC1 in Patients with Acute Spinal Cord ... GERN ) announced that the U.S. Food and Drug,Administration ... application for the clinical trial of GRNOPC1 in patients with,acute ... with,the world,s first study of a human embryonic stem (hESC) ...
Cached Biology Technology:Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 2Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 3MultiVu Video Feed: Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy 2
(Date:7/11/2014)... July 10, 2014---A team of researchers from The Chinese ... identified a gene of wild soybean linked to salt ... grow in saline soil. This study published online in ... unveil novel genomic information for crop improvement. , Soybean ... domestication and human selection, cultivated soybeans have less genetic ...
(Date:7/11/2014)... Salk Institute for Biological Studies, BGI, and other ... and reliability of the existing targeted gene correction ... which could significantly increased gene-correction efficiency in human ... online in Cell Stell Cell provides ... therapy. , The combination of stem cells and ...
(Date:7/11/2014)... often develop relationships with other group members to reduce ... chacma baboons the strategy for grooming activities shows a ... published in the scientific journal Biology Letters . ... is not practiced without ulterior motives. To be groomed ... individual, while grooming another individual can provide access to ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A new genome editing method brings the possibility of gene therapies closer to reality 2Baboons groom early in the day to get benefits later 2
... is a professional, scientific society of approximately 11,000 ... research institutes worldwide. Founded in 1986, AAPS provides ... knowledge among scientists to serve the public and ... scientific programs, on-going education, information resources, opportunities for ...
... Following the drought of 2012, the prices of ... significantly. In an effort to reduce their costs, pork ... and phosphorus (P). Researchers at the University of Illinois ... minerals in byproducts from the rendering industry. Professor ...
... Park Ridge, Ill. (April 23, 2013) This ... the world are gathering to share research on a ... growing global burden of chronic disease, there is particular ... in overall health. Several studies presented at the conference ...
Cached Biology News:2013 AAPS National Biotechnology Conference returns to San Diego 2Calculating phosphorus and calcium concentrations in meat and bone meal for pig diets 2New research points to benefits of eggs, even for those at cardiovascular risk 2
Hybridization Buffer 3.6 ml...
Olig2 Immunogen: Synthetic peptide from rat. Available Date: 9-19-2006...
Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778 ...
Proteinase K Buffer 3.9 ml...
Biology Products: